Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | MYC | P01106 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 3/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 4/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24111506 | 0.85 | MYC (0.37) | ALDH1A1HPGDLMNASMN1; SMN2NPSR1 | |
| SCHEMBL19309176 | 0.83 | PRKCQ (0.37) | ALDH1A1HPGDLMNASMN1; SMN2NPSR1 | |
| SCHEMBL21971670 | 0.82 | MYC (0.36) | ALDH1A1HPGDLMNASMN1; SMN2NPSR1 | |
| SCHEMBL24027426 | 0.82 | MYC (0.36) | ALDH1A1HPGDLMNASMN1; SMN2NPSR1 | |
| SCHEMBL20412649 | 0.81 | SQOR (0.36) | ALDH1A1HPGDLMNASMN1; SMN2NPSR1 | |
| SCHEMBL29775960 | 0.80 | NOS3 (0.52) | MYCKIF11XDHABCG2CTSS | |
| SCHEMBL9004182 | 0.80 | HDAC8 (0.37) | ALDH1A1HPGDLMNAKIF11ALOX15 | |
| SCHEMBL2334808 | 0.80 | NOS3 (0.52) | MYCKIF11XDHABCG2CTSS | |
| SCHEMBL13737546 | 0.77 | MYC (0.35) | MYCXDHABCG2CTSKCTSS | |
| SCHEMBL26050433 | 0.77 | IDH1 (0.35) | MYCXDHABCG2CTSSNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20230357294-A1 | SPIRO-CYCLOMETALATED IRIDIUM EMITTERS FOR OLED APPLICATIONS | THE UNIVERSITY OF HONG KONG (HK) | 2023-11-09 | — | — | US | disclosed |
| US-11780852-B2 | Methods for treating Crohn's disease using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780852-B2 | Methods for treating Crohn's disease using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-18 | — | — | US | disclosed |
| US-20230212199-A1 | PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230019491-A1 | PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF | EMD Serono Research and Development Institute, Inc. | 2023-01-19 | — | — | US | disclosed |
| US-11541059-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| EP-3892618-A1 | 4-PYRIDINYL FORMAMIDE COMPOUND OR DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR, HERBICIDAL COMPOSITION AND USE THEREOF | Qingdao KingAgroot Chemical Compound Co., Ltd. (CN) | 2021-10-13 | — | — | EP | disclosed |
| WO-2003080578-A1 | HETEROAROMATIC UREA DERIVATIVES AS VR-1 RECEPTOR MODULATORS FOR TREATING PAIN | MERCK SHARP & DOHME LIMITED (GB) | 2003-10-02 | — | — | WO | disclosed |
| EP-0850322-B1 | SELECTIVE SEPARATION OF DISSOLVED METAL SPECIES WITH SUBSTITUTED 1,3,5 TRIAZINE EXTRACTANTS | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2001-05-09 | — | — | EP | disclosed |
| EP-0850322-A1 | SELECTIVE SEPARATION OF DISSOLVED METAL SPECIES WITH SUBSTITUTED 1,3,5 TRIAZINE EXTRACTANTS | Commissariat à l'Energie Atomique (FR) | 1998-07-01 | — | — | EP | disclosed |
| US-5763437-A | Benzodiazepine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-09 | — | — | US | disclosed |
| WO-1998002594-A1 | SELECTIVE SEPARATION OF DISSOLVED METAL SPECIES WITH SUBSTITUTED 1,3,5 TRIAZINE EXTRACTANTS | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1998-01-22 | — | — | WO | disclosed |
| EP-0804425-A2 | BENZODIAZEPINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-11-05 | — | — | EP | disclosed |
| WO-1996004254-A2 | BENZODIAZEPINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-02-15 | — | — | WO | disclosed |
| EP-0433457-B1 | ANTIPRURITIC COMPOSITION | SHISEIDO CO LTD (JP) | 1994-10-19 | — | — | EP | disclosed |
| US-5219847-A | Antipruritic composition | SHISEIDO COMPANY, LTD. (JP) | 1993-06-15 | — | — | US | disclosed |
| EP-0433457-A1 | ANTIPRURITIC COMPOSITION | SHISEIDO COMPANY LIMITED (JP) | 1991-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357294-A1 | SPIRO-CYCLOMETALATED IRIDIUM EMITTERS FOR OLED APPLICATIONS | TALDO1, SRD5A1, SRD5A2 | ALDH1A1 191/4885HPGD 372/4885LMNA 4674/4885 |
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | ALDH1A1 2834/4885HPGD 2694/4885LMNA 4645/4885 |
| US-11780852-B2 | Methods for treating Crohn's disease using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile | ALPI, TPMT, SLC10A2 | ALDH1A1 627/4885HPGD 785/4885LMNA 2913/4885 |
| US-12043613-B2 | Inhibitors of SARM1 | SARM1, SMN1; SMN2, SARNP | ALDH1A1 4157/4885HPGD 4393/4885LMNA 1340/4885 |
| US-20230212199-A1 | PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PHOSPHO1, SGMS1, SGMS2 | ALDH1A1 3704/4885HPGD 1088/4885LMNA 878/4885 |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | ALDH1A1 164/4885HPGD 567/4885LMNA 4790/4885 |
| US-11541059-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | ALDH1A1 3154/4885HPGD 836/4885LMNA 1475/4885 |
| US-20230019491-A1 | PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF | DTYMK, TBKBP1, NFKBIA | ALDH1A1 3953/4885HPGD 1431/4885LMNA 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.